Related Guidance Notes
GNES 13: The Employer Branding Emergency
GNMA 10: Policy and public affairs for life science companies
GNMA 9: Supranational HTAs
GNMA 8: Market access for medtech, diagnostics and digital technologies in the UK
GNMA 7: Impact of Brexit on the regulatory approval process for medicines in the UK
GNMA 6: Impact of conditional approval and approval under exceptional circumstances on national pricing and reimbursement
GNMA 5: Learning from previous NICE consultations
GNMA 4: Cell and Gene Therapies – innovative contracting trends in Europe
GNMA 3: How can early access schemes support accelerated patient access in Europe?
GNMA 2: Top five reasons why products fail to achieve a positive NICE recommendation
GNMA 1: Improving access to orphan medicines
GNT 35: Tax Implications of Brexit on the Pharmaceutical Industry
GNT 52: PFICs
GNT 51: Double Tax Treaties
GNT 43: Tax Residence
GNT 33: Diverted Profits Tax
GNT 32: Setting up in the US
GNT 24: Intercompany Agreements for Transfer Pricing
GNT 23: Permanent Establishments
GNT 14: Benefits of Incorporating in the UK
GNT 13: Expansion into New Territories
GNT 11: Transfer Pricing Essentials
GNT 7: Patent Box
